Ozempic Lawsuit [September 2025 Update] | File a Claim Today

August 21, 2025: Judge Requires Gastric Emptying Study in Ozempic MDL

U.S. District Judge Karen Marston has ruled that plaintiffs in the Ozempic and related GLP-1 litigation must confirm gastroparesis diagnoses with a gastric emptying study.

The order issued on August 15 establishes a clear evidentiary requirement for all plaintiffs pursuing gastroparesis claims in the MDL.

Plaintiffs argued that other diagnostic methods should be accepted. Still, Judge Marston determined that a gastric emptying study, via scintigraphy, breath test, or wireless motility capsule, is necessary to ensure reliability.

The court observed that most reported cases involve ongoing gastroparesis, meaning plaintiffs can still undergo testing and amend their complaints.

While this ruling may exclude some claims based on prior diagnoses, it allows the MDL to move forward.

Once the remaining cross-cutting issues, including federal preemption and general causation, are resolved, the court is expected to schedule bellwether trials to assess jury reactions and potentially influence future settlements.

Over 2,400 lawsuits are still consolidated in the Eastern District of Pennsylvania.

August 20, 2025: Federal Court Allows Most Ozempic and Wegovy Claims to Proceed in MDL

A federal court has allowed the majority of claims in the multidistrict litigation (MDL) against Eli Lilly and Novo Nordisk over the weight-loss drugs Ozempic and Wegovy to proceed, rejecting defendants’ attempts to dismiss them.

Plaintiffs allege the companies misled consumers about the risks associated with the drugs, including potential side effects and safety concerns.

While some claims were dismissed or excluded from the MDL, most will continue under the consolidated litigation framework.

The decision means discovery, pretrial motions, and potential settlement discussions will move forward.

The parties are now expected to focus on evidence gathering and expert witness preparation.

No trial dates have been set at this stage.

August 18th, 2025: FDA Flags Rising Safety Concerns Over Compounded and Counterfeit Ozempic and GLP-1 Drugs

The FDA has issued a warning about serious safety risks linked to unapproved and compounded versions of GLP-1 receptor agonists, including semaglutide (the active ingredient in Ozempic and Wegovy).

These drugs, often used for weight loss, have been associated with hundreds of adverse event reports, some requiring hospitalization.

As of July 31, 2025, the FDA has received:

• 605 adverse event reports tied to compounded semaglutide
• 545 adverse event reports tied to compounded tirzepatide

Some of these reports involve serious reactions such as nausea, vomiting, abdominal pain, constipation, and dosing errors, especially when patients or providers miscalculate injections or exceed FDA-approved dosing schedules.

The agency is also investigating fraudulent compounded drugs and counterfeit Ozempic circulating in the U.S. market.

In multiple instances, product labels included false pharmacy names or referenced licensed pharmacies that never made the drugs.

In at least one case, a patient suffered injection site complications from a mislabeled product not made by the pharmacy listed.

The FDA emphasizes that many compounded semaglutide products may use salt forms (such as semaglutide sodium or acetate), which differ from the active ingredients in approved formulations and lack evidence of safety or efficacy.

Consumers are urged to avoid:

• Drugs marketed as “for research only” or “not for human consumption”
• Products sold through unauthorized online retailers
• Any medication without a valid prescription and pharmacy verification

Due to regulatory limitations, adverse event reports from state-licensed compounding pharmacies are often underreported.

However, the volume and severity of recent complaints have escalated concerns about legal accountability for unsafe and misbranded versions of GLP-1 drugs.

These findings may fuel additional product liability lawsuits against manufacturers and compounders, particularly in cases involving hospitalization, off-label dosing harm, or counterfeit exposure.

August 11th, 2025: Study Ties Ozempic to Muscle Weakness Risks

A new University of Utah Health study raises questions about potential muscle effects linked to the GLP-1 drugs, including decreased strength in some muscles despite minimal size loss.

Researchers found that in mice, semaglutide-induced weight loss mainly came from lean mass in organs like the liver, but some muscles showed decreased strength even without significant size loss.

The findings highlight concerns for older adults and others vulnerable to muscle weakness.

No human data yet confirms these effects, but the authors have stressed the need for clinical trials.

August 9th, 2025: Novo Nordisk Increases Trademark Lawsuits Over Compounded Ozempic® Products

Novo Nordisk has intensified its legal campaign to protect the Ozempic® trademark, filing 14 additional federal lawsuits against pharmacies, telehealth providers, and other sellers marketing compounded semaglutide products.

The new filings bring the total to 132 lawsuits across 40 states.

The complaints allege that defendants falsely claim their compounded semaglutide products are equivalent to, or as effective as, the FDA-approved Ozempic®, creating a risk of consumer confusion and potential safety issues.

Novo Nordisk asserts that these products may contain unapproved or unregulated active pharmaceutical ingredients.

Courts have granted 44 permanent injunctions in related cases, prohibiting certain defendants from producing or marketing compounded semaglutide as comparable to Ozempic® or Wegovy®.

Some rulings have also required defendants to forfeit profits tied to the alleged trademark violations.

The litigation follows FDA safety warnings about compounded semaglutide, which the agency does not review for safety or efficacy.

The FDA has cited reports of overdoses and other adverse events linked to such products.

Novo Nordisk has also launched public awareness efforts, including the “Check Before You Inject” campaign and the website semaglutide.com, to inform consumers about the risks of non-FDA-approved alternatives.

August 8, 2025: Litigation Grows Over Vision Loss Risks Linked to Ozempic, Wegovy, and Mounjaro

Recent studies have identified a potential link between GLP-1 receptor agonist drugs (such as Ozempic, Wegovy, and Mounjaro) and increased risks of serious eye conditions, including neovascular age-related macular degeneration (nAMD) and nonarteritic anterior ischemic optic neuropathy (NAION).

These findings have triggered a wave of new lawsuits alleging that manufacturers failed to adequately warn patients about vision loss risks.

A large observational study published in mid-2025 reported that diabetic patients using GLP-1 drugs experienced a two- to threefold increased risk of developing nAMD compared to non-users.

Although the absolute risk remains low, this association has raised concerns among medical experts and regulatory authorities.

Earlier research and case reports also suggest a significant rise in NAION cases among patients treated with semaglutide and tirzepatide, with some reports indicating up to a fourfold increase in risk.

The European Medicines Agency has recommended updating drug labels for semaglutide to include NAION as a very rare side effect, advising patients to seek immediate medical care if sudden vision changes occur.

In the United States, lawsuits related to GLP-1 drug-induced vision loss are emerging outside the initial multidistrict litigation focused on gastrointestinal injuries.

These cases are being filed in multiple jurisdictions, including a multicounty litigation in New Jersey.

Plaintiffs claim that manufacturers did not sufficiently disclose the risks of vision damage, resulting in serious and sometimes irreversible harm.

August 1st, 2025: August 2025 JPML Update

The Ozempic MDL grew to 2,190 pending cases between July and August, up from 1,997 in July.

The litigation continues to focus on allegations that GLP-1 drugs like Ozempic, Wegovy, and Mounjaro caused severe gastrointestinal injuries, including gastroparesis and intestinal obstruction.

Recent filings indicate ongoing disputes over the scope of medical record production and expert retention deadlines.

The court has yet to finalize a bellwether trial schedule.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

July 28th, 2025: Plaintiffs Seek Mass Tort Designation for Ozempic Vision Loss Cases in New Jersey

Litigation over Ozempic and Wegovy has expanded beyond gastrointestinal injuries, with over 30 plaintiffs now alleging that use of the drugs led to vision loss caused by nonarteritic anterior ischemic optic neuropathy (NAION),  a condition that can cause permanent blindness.

On July 28, 2025, plaintiffs filed a petition with the New Jersey Superior Court requesting that these Ozempic vision loss lawsuits be consolidated as multicounty litigation (MCL) in Middlesex County.

The goal is to streamline the growing number of cases, which are currently scattered across eight judges and involve plaintiffs from 13 different states.

The lawsuits claim that Novo Nordisk failed to warn patients and the medical community about the risk of NAION, despite growing evidence from multiple studies.

Allegations include failure to warn, defective design, inadequate testing, and violations of the New Jersey Consumer Fraud Act.

Lawyers argue that centralizing these cases will avoid duplication and ensure consistent rulings on shared issues of Novo Nordisk’s knowledge and warnings related to vision risks.

While this request covers only vision-related injuries, plaintiffs acknowledged a separate track may be needed if the court chooses to include existing gastrointestinal claims.

Public comments on the MCL petition are due by August 29, 2025.

July 22nd 2025: Ozempic / GLP-1 Pancreatitis Signal: U.K. Regulators Seek Patient Reports; Genetic Risk Study Underway

U.K. medicines regulators are asking anyone hospitalized with acute pancreatitis after taking a GLP-1 drug to file a Yellow Card report as part of a new investigation into whether genetics influence who develops pancreas inflammation on these widely used diabetes and weight-loss medications.

The Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England have opened enrollment through the Yellow Card Biobank, which will collect clinical details and saliva DNA samples to study patient susceptibility and improve future prescribing safety.

The call follows a rise in U.K. Yellow Card reports.

Health authorities have logged hundreds of suspected acute pancreatitis cases tied to GLP-1 medicines (nearly half involving tirzepatide) with some fatalities reported.

Current patient leaflets list pancreatitis as an “uncommon” reaction (up to ~1 in 100 users), but regulators want more data to clarify risk.

Pancreatitis concerns are not new for the drug class.

U.S. regulators flagged severe and sometimes fatal pancreatitis cases in 2007-2008 for the earlier GLP-1 drug Byetta (exenatide) and advised clinicians to stop therapy if patients develop persistent severe abdominal pain radiating to the back

In the United States, nearly 2,000 GLP-1 lawsuits—primarily alleging severe gastrointestinal injuries (gastroparesis, bowel obstruction, related complications) after Ozempic, Wegovy, Mounjaro, Trulicity, and other agents—are centralized in federal Multidistrict Litigation (MDL No. 3094) in the Eastern District of Pennsylvania.

While pancreatitis is not yet the lead injury in the MDL, emerging safety data from the U.K. investigation could influence future claims and labeling debates.

July 17, 2025: UAB Hospital Reports Increase in Ozempic and Mounjaro-Related ER Visits

A new report from UAB Hospital highlights a significant rise in emergency department visits linked to GLP-1 medications, including Ozempic and Mounjaro.

The hospital reports that overdoses and adverse reactions are rising as more patients use weight loss drugs, many without prescriptions.

UAB physicians report that patients are arriving with dangerously low blood sugar, severe nausea, and even pancreatitis, sometimes after misuse of compounded or online versions of the drugs.

While not all reported cases involve off-label or non-prescribed use, doctors highlighted the dangers of unsupervised dosing and improper titration.

This rise in reported overdoses may influence ongoing litigation regarding GLP-1 drugs, where plaintiffs claim that manufacturers did not sufficiently warn about serious gastrointestinal and metabolic risks.

Reports like UAB’s could further bolster claims of inadequate guidance on safe use and dosing.

July 15, 2025: UK Regulators Investigate Pancreatitis Risks Linked to Ozempic, Wegovy, and Mounjaro; Not Currently Part of U.S. Litigation

UK health regulators are investigating reports of pancreatitis linked to GLP-1 medications, including Ozempic (semaglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed over 560 reports of acute or chronic pancreatitis in patients using these drugs, including 10 fatalities.

The MHRA has launched a genetic study in partnership with Genomics England to examine whether certain individuals may be genetically predisposed to developing pancreatitis after taking GLP-1 medications.

The agency is also encouraging patients and healthcare providers to report cases through its Yellow Card scheme and is collecting biological samples to aid in ongoing research.

This investigation is limited to the UK and is not currently part of the U.S. litigation involving these drugs.

Lawsuits filed in the U.S. primarily focus on other alleged side effects, such as gastrointestinal injuries, including gastroparesis and intestinal obstruction.

Pancreatitis-related claims are not formally included in the scope of the U.S. multidistrict litigation (MDL) at this time

July 11, 2025: Ozempic Vision Loss Lawsuit Filed After 85% Eye Damage Alleged from NAION

A new lawsuit filed on July 10, 2025, in the U.S. District Court for the Southern District of New York alleges that use of Ozempic caused 85% vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION).

Plaintiff Geoffrey Symonds claims he developed NAION after taking Ozempic for less than three months, from November 2021 to January 2022.

The lawsuit accuses manufacturer Novo Nordisk of failing to warn patients and healthcare providers of the potential risk of vision loss.

This case follows a growing number of claims linking GLP-1 receptor agonists—such as Ozempic, Wegovy, and Mounjaro—to NAION. In June 2025, 21 similar complaints were filed in New Jersey state court seeking consolidation into a multicounty litigation.

A separate Wegovy-related NAION lawsuit was also filed in New Jersey Superior Court the same month.

In June, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION is a “very rare” side effect of semaglutide-based medications, recommending that vision risks be added to product warnings.

Recent studies from Harvard and other institutions suggest a significantly elevated risk of optic nerve damage among GLP-1 users, with some findings indicating a sevenfold increase in NAION diagnoses.

These vision loss claims remain separate from the federal multidistrict litigation (MDL 3094) involving gastrointestinal injuries allegedly caused by GLP-1 drugs, which is currently centralized in the Eastern District of Pennsylvania and includes over 1,900 cases.

Attorneys across the country continue to investigate potential vision-related injuries associated with GLP-1 agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

July 7, 2025: Ozempic Litigation Developments: Organ Damage Reports Prompt Renewed Legal and Regulatory Scrutiny

Ozempic is facing renewed safety concerns following reports of severe organ-related side effects, including pancreas, kidney, and gallbladder complications.

These developments may impact ongoing and potential litigation surrounding the drug.

Recent investigations by UK and U.S. health agencies have highlighted hundreds of cases of acute pancreatitis, some fatal, in individuals taking semaglutide-based medications such as Ozempic.

UK regulators are reportedly considering genetic screening measures to assess patient risk.

In the U.S., post-market surveillance data from 2005–2023 show over 6,700 cases of pancreatitis tied to GLP-1 drugs, leading to growing concern among healthcare providers and attorneys.

Other reported complications include acute kidney injury resulting from dehydration due to severe gastrointestinal side effects, such as vomiting and diarrhea.

The FDA has advised that kidney function should be monitored closely in high-risk patients.

Gallbladder issues, including gallstones and inflammation, have also been documented, with clinical trials showing higher incidence rates in Ozempic users compared to placebo.

In addition, the FDA has updated Ozempic’s label to include warnings about gastrointestinal obstruction and delayed gastric emptying (gastroparesis).

Emerging research has also linked long-term GLP-1 use to an elevated risk of vision problems.

While many of these side effects remain rare, the severity of outcomes has prompted increased regulatory scrutiny and legal interest.

Plaintiffs in current and potential lawsuits allege that manufacturers failed to adequately warn about serious risks associated with Ozempic and similar medications.

July 2nd, 2025: Surge in Ozempic Vision Loss Lawsuits Raises Questions About Expanding GLP-1 MDL Scope

A growing number of lawsuits are being filed against Novo Nordisk alleging that its GLP-1 receptor agonist drugs, including Ozempic and Wegovy, caused users to suffer permanent vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION).

These lawsuits are being filed independently across multiple jurisdictions and are not currently part of the existing multidistrict litigation (MDL) involving gastrointestinal injuries such as gastroparesis.

The increase in vision loss claims comes after emerging data—including a June 2025 JAMA Ophthalmology study—linked semaglutide use to significantly higher rates of NAION.

Plaintiffs allege the manufacturer failed to adequately warn about the potential for sudden and irreversible vision damage.

While the current GLP-1 drug MDL, established in the Eastern District of Pennsylvania, is focused on gastrointestinal injuries, the surge in NAION-related cases is raising the question of whether the scope of that MDL will be expanded to include additional categories of injury.

At this time, vision-related lawsuits remain outside the MDL, and no consolidation has been ordered.

However, as more claims are filed and adverse event reports continue to rise, the possibility of centralization or MDL expansion remains under consideration.

Novo Nordisk denies that a causal relationship exists between its semaglutide products and NAION and has not updated its warning labels to include vision loss as a known risk.

July 1st, 2025: July 2025 JPML Update

The Ozempic MDL grew to 1,997 total cases in July, up from 1,882 in June.

Plaintiffs continue to allege that Ozempic and other GLP-1 drugs caused severe gastrointestinal injuries such as gastroparesis, intestinal blockages, and persistent vomiting.

The court is actively managing early case proceedings, with bellwether trial selection and discovery frameworks under discussion.

Defense counsel is expected to contest causation, while plaintiffs seek access to internal safety data and adverse event reports.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

June 24th, 2025: Judge Affirms FDA Ban on Compounded Ozempic, Wegovy

U.S. District Judge Mark Pittman has approved the FDA’s decision to remove semaglutide, the active ingredient in Ozempic and Wegovy, from its drug shortage list, dismissing a lawsuit filed by the Outsourcing Facilities Association. 

The ruling prevents compounding pharmacies from continuing to make copies of the popular weight-loss medications, which they had been permitted to do under FDA rules during the declared shortage.

Pittman found that the FDA had taken into account supply and demand data, including public comments from Novo Nordisk’s CEO regarding limited access to the drugs.

The court also observed that the FDA questioned the company about those statements before reaching a decision.

Larger outsourcing facilities were required to stop compounding drugs by May 22, while smaller pharmacies had to cease by April.

This is the second loss for compounding pharmacies challenging FDA decisions regarding weight-loss drugs.

In May, Pittman dismissed a similar lawsuit concerning the removal of Eli Lilly’s Zepbound and Mounjaro from the shortage list.

That ruling is presently under appeal.

June 12th, 2025: EMA Adds Vision Loss Disorder to Ozempic, Wegovy Safety Label

The European Medicines Agency’s safety committee concluded that semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, may rarely cause non-arteritic anterior ischemic optic neuropathy (NAION).

This serious eye condition can lead to vision loss.

The EMA directed Novo Nordisk to update product labels to indicate NAION as a rare side effect, defined as occurring in up to 1 in 10,000 users after at least one year of treatment.

This marks the first time a regulatory authority has formally acknowledged the link, following multiple studies suggesting an increased risk of NAION among type-2 diabetes patients taking semaglutide.

A study conducted in March 2025 involving 350,000 patients found that two years of Ozempic use more than doubled the risk of developing the condition compared to alternative diabetes treatments.

Novo Nordisk stated that neither clinical trials nor post-marketing data suggest a “reasonable possibility” that semaglutide causes NAION.

Still, it said it will cooperate with the EMA to update the labels.

The company maintains that the benefit-risk profile remains favorable. U.S. regulators have not provided comments on whether the FDA is reviewing the issue.

June 5th, 2025: Ozempic Linked to Fertility Changes, Raising Legal Questions

Emerging reports suggest that GLP-1 medications, such as Ozempic and Wegovy, may impair fertility in both men and women, raising potential implications for future product liability claims.

Registered dietitian Ayla Barmmer told The New York Post that 15% of her GLP-1 patients have encountered fertility challenges, with 40% of that group experiencing irregular menstrual cycles, delayed ovulation, or declining sperm quality, outcomes likely tied to nutrient deficiencies resulting from rapid weight loss.

The issue is associated with significant deficiencies in protein, vitamin B12, vitamin D, iron, calcium, and folate, all of which are essential for reproductive health.

Some women have developed defects in the luteal phase, while men have experienced decreases in testosterone and sperm motility.

Clinicians have also noted that sudden caloric deficits can lead the brain to decrease reproductive hormone production as a protective mechanism.

However, GLP-1s have also been reported to improve fertility in some cases, particularly in patients with PCOS, due to their ability to enhance insulin sensitivity and reduce systemic inflammation.

This paradox highlights the complexity of potential reproductive side effects and may become relevant if claimants allege unexpected fertility harm or unsuccessful pregnancies.

Barmmer recommends that GLP-1 users planning to conceive undergo targeted nutrition therapy and consider tapering off the medication eight to ten weeks before attempting pregnancy.

June 2nd 2025: June 2025 JPML Update

The Ozempic MDL added 73 cases between May and June, bringing the total to 1,882.

New filings continue to center on gastroparesis, with plaintiffs reporting months-long vomiting, severe bloating, and repeated hospital visits after using GLP-1 receptor agonists like Ozempic and Wegovy.

Many complaints now include diagnostic imaging and gastroenterologist notes confirming delayed gastric emptying.

Lawyers are coordinating medical reviews to identify common usage patterns, including dosage escalation timelines and concurrent use with other GLP-1 drugs.

The court is expected to set initial discovery parameters in the coming weeks.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

May 27, 2025: ‘Ozempic Teeth’ Raises Concerns as Doctors Connect GLP-1 Side Effects to Oral Health Issues

Doctors and dentists are warning about “Ozempic teeth,” a term used for the dental issues increasingly reported by users of semaglutide.

Patients using Ozempic and other GLP-1 medications have reported tooth decay, gum irritation, enamel erosion, and ongoing dry mouth.

These issues seem to arise from common side effects such as dehydration, acid reflux, and vomiting, according to Dr. Sandip Sachar and Dr. Meghan Garcia-Webb.

There is no formal research connecting the drug to oral health complications.

Still, clinicians observe that reduced thirst and slower digestion—two known effects of GLP-1 medications—can lead to decreased saliva production.

The lack of saliva increases plaque buildup, making teeth more vulnerable to acid damage and decay.

Doctors suggest lowering the dose or adding medication to manage nausea if symptoms arise.

At this time, dental injuries are not accepted injuries in the Ozempic lawsuit. However, as more research is conducted and made public, attorneys will investigate and explore these potential injuries.

May 24th, 2025: FDA Cracks Down on Compounded Weight Loss Drugs

The FDA is now cracking down on compounded versions of popular weight-loss drugs like Ozempic and Zepbound, following the official end of nationwide shortages.

Compounded drugs are custom-made by pharmacies and have served as a lower-cost alternative during supply issues—often costing around $350 compared to $1,000 for the brand-name versions.

With shortages resolved, the FDA says these off-brand versions must stop production.

Officials warn that compounded semaglutide products may pose safety risks due to inconsistent dosing and lack of testing.

Some pharmacies have attempted to sidestep the crackdown by altering ingredients or dosages, raising further concern.

Doctors urge patients to use only FDA-approved medications and consult healthcare providers before starting or continuing any compounded weight-loss treatments.

As the popularity of GLP-1 receptor agonists such as Ozempic, Wegovy, and Zepbound increases, a newly reported complication known as “Ozempic feet” has become a growing concern.

This term refers to the physical changes in the feet that occur due to rapid and significant weight loss, which is often associated with these medications.

Specifically, users may experience a reduction in the natural fat padding on the soles of their feet, which can lead to discomfort, pain, and a sensation of walking directly on bone.

These changes can affect a person’s mobility and overall quality of life, potentially limiting their ability to remain active, which is essential for maintaining long-term health and preventing weight gain.

Medical professionals note that, although this condition is not life-threatening, it can lead to structural and functional issues in the feet.

The loss of cushioning may lead to increased pressure on bones, joints, and tendons, potentially altering a person’s walking pattern and adding strain to other body parts.

For individuals with preexisting conditions such as type 2 diabetes, this side effect may be particularly problematic.

People with diabetes already face increased risks of nerve damage, poor circulation, and ulcers, making it essential to monitor any new discomfort or changes in foot structure.

124 cases have been added to the Ozempic MDL in the past month.

This growth has been consistent throughout this year, with 478 cases added to the litigation since January 1st.

The rising number of claims reflects increasing awareness among users who have experienced painful and debilitating side effects.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing

A new lawsuit has been filed, alleging that Ozempic has caused severe vision loss.

A North Carolina resident filed the lawsuit on April 16 in New Jersey federal court, claiming she developed blurred and reduced vision in her left eye after using Ozempic.

This lawsuit is filed outside of the federal GLP-1 multidistrict litigation (MDL) pending in the Eastern District of Pennsylvania.

Most existing lawsuits against the manufacturers of Ozempic, Wegovy, Mounjaro, and similar drugs involve allegations of gastroparesis, ileus, intestinal obstruction, and other gastrointestinal issues.

These cases have been consolidated under the supervision of U.S. District Judge Karen S. Marston, where the court is currently addressing cross-cutting issues, including federal preemption, the sufficiency of diagnostic evidence, and general causation linking GLP-1 drugs to gastrointestinal injuries.

This new complaint, along with a few others, centers on vision loss, alleging that Novo Nordisk failed to adequately warn users about the risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition characterized by reduced blood flow to the optic nerve.

Concerns about Ozempic-related vision problems surfaced in July 2024 after a Harvard study indicated a significantly increased risk of NAION among semaglutide users.

Additional findings published in January 2025, along with actions taken by the Danish Medicines Agency, prompted further scrutiny of the drug’s vision-related side effects.

According to the lawsuit, the plaintiff used Ozempic between November 2023 and June 2024, leading to her NAION diagnosis.

She asserts claims of failure to warn, breach of warranty, fraudulent concealment, misrepresentation, design defect, negligence, and seeks both compensatory and punitive damages.

While the early bellwether trials in the GLP-1 MDL are expected to influence the broader litigation landscape and may pave the way for settlements, the vision loss lawsuit is a separate entity.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

FDA Seizes Counterfeit Ozempic Products Amid Ongoing Concerns

The U.S. Food and Drug Administration (FDA) has released a public alert after the seizure of several hundred units of counterfeit Ozempic in the United States.

Patients and healthcare providers are encouraged to confirm the authenticity of their prescriptions because of the possible distribution of counterfeit 1-milligram Ozempic injections outside the authorized supply chain.

The counterfeit products were identified by the lot number PAR0362 and the serial numbers beginning with 51746517.

The FDA confiscated these units on April 9, 2025, and has launched an investigation in collaboration with Novo Nordisk, the manufacturer of Ozempic.

Initial reports suggest that six adverse events could be linked to the affected lot, although there is presently no confirmed connection to the counterfeit drugs.

Testing continues to assess the safety and composition of the seized products.

This incident underscores growing concerns regarding the widespread use and demand for Ozempic, particularly as it is being utilized off-label for weight loss.

This follows a similar warning issued by the FDA in December 2023, when thousands of counterfeit Ozempic units were seized, and some of these are believed to still be in circulation.

Counterfeit drugs are distinct from compounded versions, which pharmacies produce under specific regulatory allowances during drug shortages.

However, the FDA previously announced in February 2025 that the supply issues related to Ozempic and its weight loss counterpart, Wegovy, have been resolved, effectively decreasing the need for compounded alternatives.

The FDA and Novo Nordisk are continuing to monitor the situation and are taking steps to prevent the further distribution of unauthorized products.

Healthcare professionals are encouraged to report any suspected counterfeit medications.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Ozempic and the GLP-1 Drug Landscape

Pfizer has officially halted the development of its experimental once-daily weight loss pill, danuglipron, due to a case of liver injury in a clinical trial participant.

This decision arises as scrutiny over the safety of GLP-1 drugs, a class that includes Ozempic, intensifies amid the growing popularity and competition in the obesity treatment market.

Although the affected patient did not show liver-related symptoms, elevated liver enzyme levels were noted, a marker of potential liver damage.

According to Pfizer, the enzymes returned to normal after the patient ceased taking danuglipron.

This case occurred during a study in which the pill’s dosage was rapidly increased, and Pfizer stated that its decision was based on a thorough review of all clinical data and regulatory feedback.

This marks Pfizer’s second withdrawal of a danuglipron formulation, following the discontinuation of a twice-daily version in December 2023 due to tolerability issues.

Despite earlier confidence in the once-daily version, Pfizer has halted its development.

However, the company stated that its latest trials still met key goals related to efficacy and tolerability.

The GLP-1 drug class, which includes Ozempic (semaglutide), Wegovy, and Mounjaro, works by mimicking gut hormones to regulate blood sugar and reduce appetite.

These medications have garnered significant attention for their weight loss benefits.

While Ozempic is approved for the treatment of Type 2 diabetes, it has also been used off-label for weight loss.

Pfizer noted that the incidence of elevated liver enzymes with danuglipron was consistent with that observed in approved GLP-1 treatments.

The overall safety of GLP-1 drugs is still being monitored as more patients start long-term use.

Pfizer remains dedicated to developing obesity treatments and is currently exploring alternative drug candidates, including a GIPR-targeting oral therapy that is in phase two trials.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

April 11, 2025: New Study Finds Rare Link Between Ozempic and Low Blood Sugar

A new study has identified a rare yet significant connection between the use of Ozempic and severe low blood sugar levels, even when the medication is taken alone.

These findings may impact ongoing legal reviews concerning the drug’s safety.

The research, conducted by the Centers for Disease Control and Prevention (CDC) and Cambridge Health Alliance, was published on April 7 in the Annals of Internal Medicine.

It examined emergency room visits associated with semaglutide drugs such as Ozempic and Wegovy.

From 2022 to 2023, approximately 24,500 emergency visits were linked to these drugs, with the majority, over 20,000, occurring in 2023.

Most visits were due to stomach issues such as nausea, vomiting, or diarrhea—typically resulting from incorrect dosing.

About 16% of cases involved low blood sugar, or hypoglycemia.

This condition can lead to serious health problems, including seizures, fainting, or stroke-like symptoms.

Low blood sugar typically poses a risk when medications like Ozempic are used alongside insulin or other drugs that reduce blood sugar levels.

However, this study identified a few instances where Ozempic was the sole medication used, yet low blood sugar still occurred.

There is also a growing concern about unapproved, compounded versions of semaglutide, which are often sold online during shortages of the official brand-name products.

Poison control centers have experienced a sharp rise in calls related to these versions, primarily because people are taking incorrect dosages.

Some accidentally took 10 times the appropriate dose because of confusing syringe instructions.

Since 2019, calls related to GLP-1 drugs like Ozempic have surged by 1,500%, with 1,678 cases already reported in 2025.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit saw an increase in filings from March to April 2025. 

In March, 1,521 total Ozempic Lawsuits were filed.

By April 1st, the JPML reported that the number of Ozempic Lawsuits grew to 1,685, marking an increase of 164 new filings.

The Ozempic Lawsuit centers around allegations that the use of the type 2 diabetes drug has led to severe side effects, including gastrointestinal issues, pancreatitis, and other serious health conditions.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Plaintiffs in the growing litigation over GLP-1 medications like Ozempic, Wegovy, and Mounjaro have asked a federal judge to reject efforts by Novo Nordisk and Eli Lilly to dismiss most of the claims brought against them.

In a filing submitted March 18, plaintiffs argue that the drug makers overstated the benefits of GLP-1 drugs while minimizing the risk of serious gastrointestinal injuries, including gastroparesis, ileus, and intestinal obstruction.

More than 1,500 lawsuits have been consolidated before U.S. District Judge Karen Marston in the Eastern District of Pennsylvania, forming a multidistrict litigation (MDL) involving users of the diabetes and weight-loss drugs.

Plaintiffs allege the manufacturers failed to warn about life-altering GI complications while aggressively marketing the drugs as near-miracle weight-loss solutions.

In January, the manufacturers moved to dismiss most claims in the MDL’s Master Complaint, arguing that only the failure-to-warn claims may be valid.

But plaintiffs counter that their lawsuit details a much broader scheme of deceptive marketing, negligent misrepresentation, breach of warranty, and design defect.

“Defendants ignored known risks to maximize profits,” the filing states.

“Their campaign directly influenced patient decisions and altered prescribing behaviors through overstated promises and withheld safety data.”

The court still must resolve several cross-cutting issues, including whether the claims are preempted by federal law and whether plaintiffs need specific diagnostic testing to prove injury.

If the cases proceed, Judge Marston is expected to schedule bellwether trials to help evaluate how juries respond to the evidence.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

In recent months, a growing number of individuals who used GLP-1 medications like Ozempic, Mounjaro, and Wegovy for weight loss and Type 2 diabetes management have reported severe vision-related side effects, including non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden and often irreversible vision loss.

Among those affected is James Norris, a 56-year-old mechanic, who experienced blurred vision in both eyes after using Mounjaro.

He had been prescribed the medication in 2023 and saw significant weight loss and improvement in his health, but within a year, his vision rapidly deteriorated.

Norris and others have now filed lawsuits against the manufacturers, including Novo Nordisk, the maker of Ozempic and Wegovy, and Lilly, the maker of Mounjaro.

Studies published in January and July 2024 showed an increased risk of NAION for patients using these drugs, with individuals who took them for weight loss at an even higher risk.

Despite these findings, the medications’ manufacturers have not added explicit warnings about NAION to their product labels, leaving patients unaware of the serious consequences.

The legal claims include accusations of deceptive marketing and failure to inform the medical community about the risks of vision impairment linked to the drugs.

Attorneys representing the plaintiffs argue that patients, who used these medications in good faith to manage their weight or diabetes, suffered devastating consequences without being informed of the potential for vision damage.

As more patients come forward with similar complaints, the number of lawsuits is expected to rise, creating growing pressure on the manufacturers to address the risks associated with their products.

Novo Nordisk and Lilly, in response to these allegations, have stated that they take patient safety seriously and continuously monitor the safety of their medications.

However, patients and their legal representatives argue that these actions came too late, and the lack of a clear warning on the drugs has resulted in life-altering consequences for many users.

This wave of lawsuits follows recent studies showing a clear correlation between these medications and an increased likelihood of developing serious eye conditions, with some cases leading to permanent blindness.

For patients like Cheryl Bovee, who is now legally blind after taking Ozempic, the medication’s benefits have been overshadowed by its devastating side effects.

Bovee, who filed her lawsuit against Novo Nordisk in February 2025, claims that the company’s marketing of Ozempic was misleading and deceptive, failing to disclose the potential for severe vision loss.

As these cases develop, more patients who have experienced vision issues while using Ozempic, Mounjaro, or Wegovy are expected to join the lawsuits.

The outcome of these legal actions could have significant implications for the pharmaceutical industry, potentially leading to new regulations around the labeling and marketing of medications used for weight loss and diabetes management.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A federal judge has ruled against compounding pharmacies’ ability to produce their own versions of Eli Lilly’s diabetes and weight loss drugs, Zepbound and Mounjaro.

The decision, issued by Judge Mark Pittman of the Northern District of Texas, follows a lawsuit filed by the Outsourcing Facilities Association (OFA) in October.

The OFA claimed the FDA’s decision to remove tirzepatide, the active ingredient in these drugs, from its shortage list would deprive patients of vital treatments and raise drug prices.

This ruling effectively halts the production of compounded versions of these medications, which had been allowed during the shortage period.

The FDA had paused enforcement after the lawsuit was filed but reaffirmed its stance in December.

Smaller state-licensed pharmacies were given until February 18 to stop making compounded tirzepatide, and larger outsourcing facilities must cease production by March 19.

The OFA has signaled plans to appeal, with similar litigation ongoing regarding semaglutide, the active ingredient in Ozempic.

Eli Lilly praised the ruling, claiming it would eliminate risky, unapproved knockoffs of the drugs.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

After more than two years of supply issues, the shortage of Ozempic and Wegovy has officially ended, according to the FDA.

Novo Nordisk reports that production has stabilized, allowing the company to meet current and future demand in the U.S.

Despite this, some delays may persist as shipments move through distribution channels.

Patients should check with their pharmacies regarding availability.

Additionally, compounding pharmacies will be required to phase out off-brand versions of semaglutide in the coming months.

The resolution of supply issues comes as lawsuits continue to be filed against Novo Nordisk by individuals who suffered severe gastrointestinal injuries and other complications after taking Ozempic and other GLP-1 drugs.

These claims allege that the manufacturer failed to adequately warn consumers about the risks associated with the drug.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

In February 2025, the number of Ozempic lawsuit cases rose to 1,443, reflecting an increase of 112 cases compared to January 2025, where the total stood at 1,331.

This uptick in filings can be attributed to ongoing concerns regarding Ozempic’s side effects, with plaintiffs claiming various health complications caused by the medication.

The rise in litigation highlights growing awareness of potential risks associated with the drug and increased legal action from those affected.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

A recent study has raised alarm over websites selling compounded versions of popular weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, often without disclosing crucial safety risks.

Researchers reviewed 79 websites advertising compounded GLP-1 receptor agonists, like semaglutide and tirzepatide, and found significant lapses in transparency.

Key Findings:

• Over half of the websites failed to disclose that their products were not FDA-approved.
• 37% misleadingly implied FDA approval, while 14% did not clarify they were selling compounded versions.
• Roughly 50% omitted critical information about side effects, precautions, and warnings.
• Around 40% overstated the benefits of these drugs, potentially creating false expectations.

The study highlights the risks associated with compounded drugs, which are often made during shortages of branded medications but lack FDA verification for safety or efficacy.

The ongoing tight supply of Wegovy and Zepbound has fueled demand for these alternatives, which are being sold at prices ranging from $231 to $330 for the first month.

Experts, including outgoing FDA Commissioner Robert Califf, have expressed concerns about the safety of internet compounding pharmacies, warning that patients may not know what they are purchasing.

Researchers and commentators have called for stricter oversight of advertisements for compounded drugs, urging them to meet the same standards as FDA-approved prescription medications.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

The federal multidistrict litigation (MDL) over Ozempic and other GLP-1 drugs continues to expand, now encompassing claims related to Saxenda but remaining focused on gastrointestinal injuries like gastroparesis, small bowel obstruction, and gallbladder issues.

A critical evidentiary hearing is set for May 14, 2025, where U.S. District Judge Karen Marston will evaluate whether plaintiffs have presented sound scientific evidence linking these drugs to alleged injuries.

This “cross-cutting” issue is pivotal, as plaintiffs must establish general causation to proceed with their claims.

Currently, the litigation includes over 1,300 lawsuits against Novo Nordisk and Eli Lilly, with numbers expected to grow as more individuals report complications like stomach paralysis and intestinal blockages.

Given the broad use of GLP-1 drugs, the scope of this MDL could reach tens of thousands of claims in 2025.

Regular status conferences will be held throughout the year, while fact discovery on causation is slated to conclude by July 2025.

Trials are not expected to begin until late 2026 or early 2027, with outcomes likely influencing future settlement negotiations.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit is ongoing. 

The Ozempic Lawsuit focuses on claims that the diabetes and weight loss medication Ozempic has caused severe gastrointestinal side effects, including gastroparesis, nausea, and vomiting.

Plaintiffs allege that the manufacturers of these drugs, Novo Nordisk and Eli Lily, failed to adequately warn users of these risks.

In December, 1,300 cases were pending in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.

The number of Ozempic Lawsuits pending in the MDL has increased to 1,331 in January, with 31 new claims added.

Gastroparesis and related complications can significantly impact quality of life, often requiring ongoing medical intervention.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.